Treatment of leiomyomatosis peritonealis disseminata with goserelin acetate: A case report and review of the literature

Table 3 Characteristics of four leiomyomatosis peritonealis disseminata cases treated with goserelin acetate

Case No.	Ref.	Age	Obstetric history	UL history; treatments	OC use/HRT	Symptoms	ER/PR status	Treatments	Response
1	Verguts et al[26], 2014	21	Unknown	Yes; hysteroscopic resection	No/No	Abdominal discomfort	Negative/positive	Goserelin acetate and tibolone × 2 yr → ulipristal acetate × 1 yr	+, +
2	Nassif et al[31], 2016	45	G1P1	Yes; unknown	Yes/No	Dorsal pain	Positive/unknown	Goserelin acetate × 6 mo → Progestin × 6 mo	+, treatment for UL
3	Quaranta et al[19], 2018	60	P3	Yes; unknown	No/No	Abdominal discomfort and postmenopausal bleeding	Strongly positive/strongly positive	Goserelin acetate	LPD recurred within one year
4	Ando et al[24], 2017	40	G0	Yes; transcervical resection	No/No	Abdominal pain	Slightly positive/slightly positive	Goserelin acetate 1.8 mg monthly × 6 mo → TAH, BSO and tumor resection → letrozole	+, LPD recurred 6 mo after surgery, +

OC: Oral contraceptives; HRT: Hormone replacement treatment; TAH: Total abdominal hysterectomy; BSO: Bilateral salpingo-oophorectomy; +: Successful control of leiomyomatosis peritonealis disseminate; LPD: Leiomyomatosis peritonealis disseminate; UL: Uterine leiomyoma; ER: Estrogen receptors; PR: Progesterone receptors.